Although Syk inhibitors are beneficial in several autoimmune diseases [36] and some hyper-inflammatory situations [37, 38], Syk inhibitors might be even more effective in the lupus caused by FcγR polymorphism with leaky gut-induced endotoxemia and/or glucanemia. Here, FCGR2A is linked to serum lipopolysaccharide activity.